M&A - Synergy Empire Ltd

Form Type: 8-K

Filing Date: 2025-04-03

Corporate Action: Acquisition

Type: New

Accession Number: 000164117225002536

Filing Summary: On April 3, 2025, Synergy Empire Limited announced the completion of its acquisition of Meluha Therapeutics Berhad, a biopharmaceutical company based in Malaysia. The acquisition was carried out through an Acquisition and Stock Purchase Agreement executed on July 29, 2024, whereby Synergy Empire agreed to purchase all outstanding shares of Meluha for a total consideration of $2,300,000, issued as 10,000,000 shares of Series A preferred stock. The acquisition was finalized on March 28, 2025, marking a strategic shift in Synergy Empire's focus from the food and beverage industry to the healthcare and pharmaceutical sectors. Meluha specializes in the manufacture and wholesale of biopharmaceutical and medical products, including innovative cell-based and exosome-based medicines. This acquisition allows Synergy Empire to leverage Meluha’s expertise and expanding market potential in regenerative medicine, addressing growing healthcare demands in Malaysia and Southeast Asia. Meluha is recognized for its advanced regenerative products, including myCell and Chondrogen, tailored to treat osteoarthritis and knee cartilage defects. The move is expected to enhance Synergy Empire’s operational efficiency and contribute to long-term growth.

Document Link: View Document